Development Programs

Graft versus Host Disease ("GVHD")

Kalytera is developing a clinical-stage cannabidiol (“CBD”) medicine to prevent and treat Graft versus Host Disease (“GVHD”). GVHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GVHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GVHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death.

Acute and Chronic Pain

Kalytera has initiated a novel program for the treatment of acute and chronic pain through the development of a compound that consists of a cannabinoid conjugated with naproxen, a generic, non-steroidal, anti-inflammatory drug that is already approved for treatment of pain. The objective of Kalytera’s new program is to develop a potent, non-psychotropic, oral analgesic for intractable pain that will be safe and well tolerated.

Additional Preclinical Programs

Kalytera seeks to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. By modifying cannabinoid molecules, and molecules which regulate the endogenous cannabinoid signaling system, Kalytera seeks to improve pharmacokinetics and increase potency, potentially allowing for the development of drug candidates with improved activity.

  • Acne
  • Sepsis-induced Acute Renal Failure (“ARF”)
  • Severe Traumatic Brain Injury (“TBI”)
  • Adult Respiratory Distress Syndrome (“ARDS”)
  • Ulcerative Colitis (“UC”)